Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID.
We describe three males with X-linked SCID (X-SCID) who were successfully treated by reduced-intensity SCT from unrelated cord blood (CB). Mean age at transplant was 5.7 months (range, 3-9 months). Pre-transplant conditioning for all patients consisted of fludarabine (FLU) (30 mg/m(2) per day) from day -7 to day -2 (total dose 180 mg/m(2)) and BU 4 mg/kg per day from day -3 to day -2 (total dose 8 mg/kg). All CB units were serologically matched at HLA-A, B and DR loci. Although two patients had suffered from fungal or bacterial pneumonia before transplantation, there were no other infectious complications during transplantation. All patients engrafted and achieved 100% donor chimerism. We also confirmed full donor chimerism of both T and B cells. Only one patient developed acute GVHD grade III, which was resolved by increasing the dose of oral corticosteroid. None of the patients has developed chronic GVHD during follow up for 21-77 months. None of the patient received i.v. Ig replacement post transplant, or showed delay in psychomotor development. Reduced-intensity conditioning consisting of FLU and BU and transplantation from unrelated CB was an effective and safe treatment for these patients with X-SCID.
Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan. igurin66@med.hokudai.ac.jp
A
A
Iguchi
N
N
Kawamura
R
R
Kobayashi
S-I
SI
Takezaki
Y
Y
Ohkura
J
J
Inamoto
J
J
Ohshima
M
M
Ichikawa
T
T
Sato
M
M
Kaneda
Y
Y
Cho
M
M
Yamada
I
I
Kobayashi
T
T
Ariga
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D036101:Cord Blood Stem Cell Transplantation; D005260:Female; D005312:Fetal Blood; D006086:Graft vs Host Disease / Q000209:etiology / Q000628:therapy; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D008172:Lung Diseases, Fungal / Q000209:etiology / Q000628:therapy; D008297:Male; D018410:Pneumonia, Bacterial / Q000209:etiology / Q000628:therapy; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D053632:X-Linked Combined Immunodeficiency Diseases / Q000628:therapy*
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine
Blood. 2001 May 15;97(10):2962-71
11342418
Am J Clin Oncol. 1982 Dec;5(6):649-55
7165009
N Engl J Med. 1999 Feb 18;340(7):508-16
10021471
J Clin Oncol. 2000 Sep 15;18(18):3273-9
10986060
Blood. 1986 Jul;68(1):119-25
3521761
Cancer Res. 2000 Oct 1;60(19):5470-8
11034090
Blood. 1999 Jun 15;93(12):4109-15
10361107
J Pharmacol Exp Ther. 2003 Jun;305(3):1098-103
12606622
Bone Marrow Transplant. 2004 May;33(10):1049-56
15048143
Blood. 1998 May 15;91(10):3646-53
9573000
Blood. 2001 May 15;97(10):2957-61
11342417
JAMA. 2006 Feb 1;295(5):508-18
16449616
J Allergy Clin Immunol. 2009 Sep;124(3):522-7
19482345
Bone Marrow Transplant. 2003 Jan;31(2):133-6
12621496
Bone Marrow Transplant. 2005 Aug;36(4):295-9
15968287
J Clin Oncol. 2008 Mar 20;26(9):1519-25
18268357
J Pediatr. 2001 Apr;138(4):570-3
11295723
Br J Haematol. 2008 Oct;143(2):268-73
18699848
Blood. 1998 Feb 1;91(3):756-63
9446633
Pediatr Blood Cancer. 2010 Mar;54(3):437-43
19911420
JAMA. 2009 Dec 9;302(22):2465-70
19996402
Bone Marrow Transplant. 2001 Jun;27(11):1173-80
11551028
Leukemia. 2000 Jul;14(7):1185-90
10914540
Immunol Rev. 2005 Feb;203:98-109
15661024
Blood. 2001 Feb 1;97(3):631-7
11157478
J Clin Immunol. 2000 Nov;20(6):466-76
11202237
Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S49-S52
18724301
Lancet. 2003 Feb 15;361(9357):553-60
12598139
Bone Marrow Transplant. 2006 Mar;37(5):469-77
16435016
Blood. 2005 Jan 15;105(2):879-85
15367433
Leukemia. 2007 Oct;21(10):2109-16
17690701
Blood. 1996 Aug 1;88(3):795-802
8704232
Bone Marrow Transplant. 2008 Apr;41(7):627-33
18084339
N Engl J Med. 1997 Aug 7;337(6):373-81
9241126